Since IGFBP6 is a direct antagonist of IGF-II, the lower availability of free IGFs in RA serum may be explained by increased binding to circulating IGFBP6 that, according to our data, is enhanced in RA compared to HD. This evidence concerns the gene IGF2 and rheumatoid arthritis.